| 谈弘1 张艺1 徐浩2 胡孝贞3△.波生坦治疗特发性肺动脉高压的疗效与安全性观察[J].,2012,12(11):2104-2106 |
| 波生坦治疗特发性肺动脉高压的疗效与安全性观察 |
| Clinical Efficacy and Safety of Bosentan Therapy for Idiopathic PulmonaryArterial Hypertension |
| |
| DOI： |
| 中文关键词: 波生坦 特发性肺动脉高压 疗效 安全性 |
| 英文关键词: Bosentan Idiopathic pulmonary hypertension Efficacy Security |
| 基金项目: |
|
| 摘要点击次数: 810 |
| 全文下载次数: 1016 |
| 中文摘要: |
| 目的：探讨波生坦治疗特发性肺动脉高压(IPAH)的疗效与安全性。方法：16 例IPAH 患者予波生坦口服治疗20 周，比较治
疗前后患者心功能、6 分钟步行距离(6MWD)、肺动脉压力以及血常规、肝肾功能变化。结果：患者心功能由治疗前Ⅲ级13 例、Ⅳ级
3 例变为Ⅱ级14 例、Ⅲ级2 例。6MWD 较治疗前明显延长(P<0.01)，肺动脉收缩压、肺动脉平均压及肺动脉舒张压均较治疗前显
著降低(P<0.01)，患者血常规、肝肾功能较治疗前无明显变化。结论：口服波生坦治疗IPAH 可明显改善患者的临床症状与血流动
力学指标，安全性好。 |
| 英文摘要: |
| Objective: To investigate the efficacy and safety on the treatment of bosentan in idiopathic pulmonary arterial hypertension
(IPAH). Methods: 16 patients with IPAH were treated with oral bosentan for 20 weeks. Cardiac function, 6-minute walk distance
(6MWD), pulmonary artery pressure, liver and kidney function changes were compared before and after the treatment. Results: After
treatment, 13 cases with grade Ⅲ and 3 cases with grade Ⅳ of cardiac function turned into 14 cases with grade Ⅱ and 2 cases with grade
Ⅲ. 6MWD was significantly longer than that before treatment (P<0.01). Pulmonary artery systolic pressure, mean pulmonary artery pressure
and pulmonary artery diastolic pressure was significantly lower than before treatment (P<0.01). There were no significant changes in
liver and kidney function of the patients before and after treatment. Conclusions: Oral bosentan therapy in patients with IPAH can significantly
improve the clinical symptoms and hemodynamics, which has good security. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
